Trials and Research Search | SIU School of Medicine

Showing: 8 Results

Trial

Pulmonary and Critical Care

A randomized, double-blind, placebo-controlled dose escalation and verification clinical study to assess the safety and efficacy of pulsed, inhaled nitric oxide in subjects at risk of pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy

Active recruiting

The purpose of this study is to determine if the study drug, inhaled nitric oxide (iNO), when given and breathed through an investigational study device, the INOpulse, may help treat patients at risk for pulmonary hypertension-pulmonary fibrosis. Another purpose of this study is to determine if using the INOpulse delivery device (drug and device combination) improves the levels of moderate to vigorous physical activity (for example walking, climbing stairs, household chores and cleaning and, exercise and hobbies), as measured by actigraphy (a non-invasive way to monitor rest/activity).

Trial

Neurology

AbbVie: A prospective observational study to evaluate the clinical outcomes and burden of disease of PD patients with motor fluctuations not adequately controlled by current PD medications.

Active not recruiting

PROSPECT: This is an observational study and is designed to describe the clinical outcomes and the burden of disease in PD patients with motor fluctuations not adequately controlled by current PD medications.

Trial

Neurology

Caregiver Characteristics That May Predict When Patients With Alzheimer Disease Are Placed in Long Term Care Facilities

Active recruiting

This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois. AD patients and their caregivers who are living in private homes will be recruited. Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13 The patient and caregiver dyad is required.

Trial

Neurology

Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Active not recruiting

I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior. Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.

Trial

Neurology

MDA: Neuromuscular Observational Research

Active recruiting

MOVR: Data Hub is the first and only data hub that aggregates clinical, genetic, and patient reported data for multiple nuromuscular diseases. Collection of patient data about disease progression in the era of new treatments will inform and accelerate future innovation. The combination of data collected through MOVR Data Hub will provide a comprehensive understanding of health and patient experiences in a single data repository. MOVR Data Hub has the power to transform health outcomes, accelerate drug development and drive clinical research across multiple neuromuscular diseases, helpin

Trial

Neurology

Roche: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of MTAU9937A in Patients with Moderate Alzheimer's Disease

Active not recruiting

Lauriet: The purpose of this study is to compare the effects, good or bad, of MTAU9937A versus placebo on patients with moderate AD. In this study, you will get either MTAU9937A or placebo. MTAU9937A is an experimental drug, which means health authorities such as the Food and Drug Administration (FDA) have not approved it for the treatment of moderate AD or other conditions. MTAU9937A is in early development and has been previously studied in healthy subjects and people with milder forms of Alzheimer’s disease.

Trial

Neurology

Roche: A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson's disease

Active recruiting

PADOVA: The purpose of this study is to find out what effects, good and/or bad, prasinezumab versus placebo has on Parkinson’s disease in people who are taking standard medication to manage the disease symptoms.

Trial

Neurology

Roche: An open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term gantenerumab administration in participants with Alzheimer's disease

Active not recruiting

POST GRAD: The purpose of this study is to compare the effects, good or bad, of long term gantenerumab on subjects with prodromal or mild Alzheimer's disease.

Clinical trials and research studies